1.38%
12.33%
22.03%
25.71%
-27.46%
-18.58%
46.69%
AI Spotlight on DXCM
Company Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.The company provides its systems for use by people with diabetes, as well as for use by healthcare providers.Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.
The company's products candidature comprises Dexcom G7, a next generation G7 CGM system.DexCom, Inc.has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products.
The company markets its products directly to endocrinologists, physicians, and diabetes educators.DexCom, Inc.was incorporated in 1999 and is headquartered in San Diego, California.
Market Data
| Last Price | 87.62 |
| Change Percentage | 1.38% |
| Open | 86.61 |
| Previous Close | 86.43 |
| Market Cap ( Millions) | 34224 |
| Volume | 2123116 |
| Year High | 142 |
| Year Low | 62.34 |
| M A 50 | 79.75 |
| M A 200 | 91.05 |
Financial Ratios
| FCF Yield | 1.56% |
| Dividend Yield | 0.00% |
| ROE | 31.20% |
| Debt / Equity | 130.93% |
| Net Debt / EBIDTA | 201.99% |
| Price To Book | 17.45 |
| Price Earnings Ratio | 50.73 |
| Price To FCF | 63.97 |
| Price To sales | 8.66 |
| EV / EBITDA | 37.11 |
News
- Jan -30 - Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time.
- Jan -21 - DXCM's Preliminary Results Show Strong Growth: How to Play the Stock?
- Jan -17 - DexCom: Fairly Priced In 2025; Why I'm Not Expecting A Share Price Comeback
- Jan -16 - 2 Healthcare Stocks to Buy Hand Over Fist in January
- Jan -14 - DexCom Stock Up Following Strong Preliminary Q4 Results & 2025 Outlook
- Jan -13 - Dexcom forecasts 2025 revenue mostly in-line with expectations
- Jan -13 - Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
- Jan -08 - 3 Beaten-Down Stocks That May Be Due for Big Comebacks in 2025
- Jan -04 - These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024
- Dec -23 - Abbott and DexCom settle glucose monitor patent disputes
- Dec -23 - DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock?
- Dec -21 - 1 Reason to Sell DexCom Stock, and 1 Reason to Buy
- Dec -20 - 2025 Picks: 2 Stocks to Buy Now for 50% Upside
- Dec -19 - Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement
- Dec -18 - DXCM Stock Gains on the Launch of Proprietary Generative AI Platform
- Dec -17 - Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels
- Dec -17 - Dexcom Launches the First Generative AI Platform in Glucose Biosensing
- Dec -17 - Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM
- Dec -13 - Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
- Dec -10 - DexCom: Brighter 2025 From Stelo Ramp
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Distributor
Expected Growth : 12 %
What the company do ?
Distributor from DexCom, Inc. is a supplier of continuous glucose monitoring systems for diabetes management, providing real-time glucose data to healthcare professionals and patients.
Why we expect these perspectives ?
Strong demand for continuous glucose monitoring systems, increasing adoption of DexCom's G6 and G7 systems, expansion into new markets, and growing partnerships with insulin manufacturers and healthcare providers drive the 12% growth of the distributor segment.
Segment n°2 -> Direct
Expected Growth : 18 %
What the company do ?
Direct from DexCom, Inc. is a continuous glucose monitoring system that sends real-time glucose data directly to a compatible smart device.
Why we expect these perspectives ?
DexCom's 18% growth driven by increasing adoption of continuous glucose monitoring systems, expanding diabetes patient population, and growing awareness of digital health technologies. Additionally, strategic partnerships, innovative product pipeline, and expanding global presence contribute to the company's rapid growth.
Dexcom, Inc. Products
| Product Range | What is it ? |
|---|---|
| G6 CGM System | A continuous glucose monitoring system that provides real-time glucose readings every 5 minutes, with a sensor that can be worn for up to 10 days. |
| G6 Pro CGM System | A professional continuous glucose monitoring system designed for healthcare professionals to use with their patients, providing detailed glucose data to inform treatment plans. |
| Dexcom CLARITY | A diabetes management software that provides a comprehensive view of glucose data, trends, and patterns, enabling more informed decision-making. |
| Dexcom G4 PLATINUM CGM System | A continuous glucose monitoring system that provides real-time glucose readings every 5 minutes, with a sensor that can be worn for up to 7 days. |
DexCom, Inc.'s Porter Forces
Threat Of Substitutes
DexCom, Inc. has a low threat of substitutes due to its strong brand recognition and patented technology in the continuous glucose monitoring market.
Bargaining Power Of Customers
DexCom, Inc. has a medium bargaining power of customers due to the presence of multiple competitors in the market, but its strong brand loyalty and customer retention rates mitigate this risk.
Bargaining Power Of Suppliers
DexCom, Inc. has a low bargaining power of suppliers due to its strong relationships with suppliers and the availability of multiple suppliers for its components.
Threat Of New Entrants
DexCom, Inc. has a medium threat of new entrants due to the high barriers to entry in the continuous glucose monitoring market, including regulatory hurdles and high research and development costs.
Intensity Of Rivalry
DexCom, Inc. operates in a highly competitive market with several established players, leading to a high intensity of rivalry in the continuous glucose monitoring market.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 55.63% |
| Debt Cost | 3.95% |
| Equity Weight | 44.37% |
| Equity Cost | 10.07% |
| WACC | 6.66% |
| Leverage | 125.40% |
DexCom, Inc. : Quality Control
DexCom, Inc. passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| BSX | Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company … |
| ABT | Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. … |
| SYK | Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use … |
| TMO | Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences … |
| DHR | Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Abbott
A-Score
1-Year Total Return ->
🥈
Stryker
A-Score
1-Year Total Return ->
🥉
Boston Scientific
A-Score
1-Year Total Return ->
4
Thermo Fisher
A-Score
1-Year Total Return ->
5
Danaher
A-Score
1-Year Total Return ->
6
